SILVER SPRING, MD, April 10, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Prof. Ann Simpson (a member of PharmaCyte
Read more →Newswise — Ascites is the buildup of fluid in the abdominal cavity that occurs in patients with certain diseases. Ascites caused by cancer is called malignant ascites and accounts for 10% of people with ascites. Malignant ascites appears most often in people with breast, colon, liver, gastrointestinal tract (stomach and intestines), and ovarian, pancreatic, and
Read more →SILVER SPRING, MD, March 27, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested
Read more →NEW YORK, NY–(Marketwired – March 18, 2015) – PharmaCyte Biotech (PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the
Read more →SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the
Read more →SILVER SPRING, Md., March 9, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its new website is now live and can be viewed at www.PharmaCyteBiotech.com. PharmaCyte Biotech’s new website
Read more →SILVER SPRING, Md., Feb. 24, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), announced today that Dr. Matthius Lohr, Chairman of its Scientific Advisory Board, together with his colleagues Dr. Verbeke, Dr. Severin Karlsson
Read more →SILVER SPRING, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low
Read more →SILVER SPRING, Md., Feb. 13, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies
Read more →